S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Gilead Sciences Stock Forecast, Price & News

$68.93
-1.72 (-2.43%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
$68.64
$70.90
50-Day Range
$64.88
$71.69
52-Week Range
$56.56
$73.34
Volume
15.47 million shs
Average Volume
7.22 million shs
Market Capitalization
$86.46 billion
P/E Ratio
11.76
Dividend Yield
4.02%
Beta
0.34
30 days | 90 days | 365 days | Advanced Chart
Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.


Gilead Sciences logo

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
13,600
Year Founded
1987

Sales & Book Value

Annual Sales
$24.69 billion
Cash Flow
$8.17 per share
Book Value
$14.54 per share

Profitability

Net Income
$123 million
Pretax Margin
33.96%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,254,384,000
Free Float
1,252,879,000
Market Cap
$86.46 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
9/14/2021
Dividend Payable
9/29/2021
Last Earnings
10/28/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/03/2022

Social Links


MarketRank

Overall MarketRank

3.53 out of 5 stars

Medical Sector

1st out of 1,390 stocks

Biological Products, Except Diagnostic Industry

1st out of 202 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -












Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

Is Gilead Sciences a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gilead Sciences stock.
View analyst ratings for Gilead Sciences
or view top-rated stocks.

How has Gilead Sciences' stock been impacted by COVID-19?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GILD stock has decreased by 6.5% and is now trading at $68.93.
View which stocks have been most impacted by COVID-19
.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Thursday, October, 28th. The biopharmaceutical company reported $2.65 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.72 by $0.93. The biopharmaceutical company earned $7.42 billion during the quarter, compared to analysts' expectations of $6.31 billion. Gilead Sciences had a net margin of 26.91% and a trailing twelve-month return on equity of 56.59%. The business's quarterly revenue was up 12.8% compared to the same quarter last year. During the same period last year, the firm earned $2.11 EPS.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, October 28th. Shareholders of record on Wednesday, December 15th will be given a dividend of $0.71 per share on Thursday, December 30th. This represents a $2.84 annualized dividend and a yield of 4.12%. The ex-dividend date of this dividend is Tuesday, December 14th.
View Gilead Sciences' dividend history
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.02%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Gilead Sciences is 48.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 42.14% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of $7.900-$8.100 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.180. The company issued revenue guidance of $26 billion-$26.30 billion, compared to the consensus revenue estimate of $25.12 billion.

What price target have analysts set for GILD?

15 Wall Street analysts have issued 12-month price targets for Gilead Sciences' stock. Their forecasts range from $66.00 to $625.00. On average, they anticipate Gilead Sciences' share price to reach $124.58 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts' price targets for Gilead Sciences
or view top-rated stocks among Wall Street analysts.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Daniel P. O'Day, Chairman & Chief Executive Officer
  • Andrew D. Dickinson, Chief Financial Officer
  • Merdad V. Parsey, Chief Medical Officer
  • Flavius Martin, Executive Vice President-Research
  • Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP (LinkedIn Profile)

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.64%), Capital Research Global Investors (9.13%), Capital World Investors (2.95%), Geode Capital Management LLC (1.78%), Morgan Stanley (1.23%) and Bank of New York Mellon Corp (1.01%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Capital Research Global Investors, Natixis, Franklin Resources Inc., Citadel Advisors LLC, Arrowstreet Capital Limited Partnership, Healthcare of Ontario Pension Plan Trust Fund, and State of Michigan Retirement System. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Johanna Mercier, and Richard James Whitley.
View insider buying and selling activity for Gilead Sciences
or view top insider-selling stocks.

Which major investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Morgan Stanley, EP Wealth Advisors LLC, MFA Wealth Advisors LLC, Nordea Investment Management AB, Capital World Investors, First Horizon Advisors Inc., and Assenagon Asset Management S.A..
View insider buying and selling activity for Gilead Sciences
or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $68.93.

How much money does Gilead Sciences make?

Gilead Sciences has a market capitalization of $86.46 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $5.86 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 13,600 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

Where are Gilead Sciences' headquarters?

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at [email protected], or via fax at 650-578-9264.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.